MedTrace Logo

Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea

NCT03633344 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2019-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to demonstrate the antidiarrheal efficacy of colloidal silicon dioxide in tablet dosage form (Carbowhite) in patients with acute diarrhea.

Conditions

  • Diarrhoea;Acute

Interventions

DRUG

Carbowhite

DRUG

Carbowhite placebo

Sponsors & Collaborators

  • Omnifarma Kiev LLC

    lead INDUSTRY

Principal Investigators

  • Oleg Kurchenko · Omnifarma Kyiv LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-29
Primary Completion
2016-10-07
Completion
2016-10-07

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633344 on ClinicalTrials.gov